Physician profile
Robert J Oliva
NPI 1740393255
$4,449.79
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,467 · 2020: $348 · 2021: $256 · 2022: $772 · 2023: $958 · 2024: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $617.11 | 2019-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $611.56 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $459.10 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $317.15 | 2019-2024 | Fasenra, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $238.15 | 2022-2023 | |
| Exact Sciences Corporation | $218.50 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $200.31 | 2022-2024 | |
| Penumbra, INC. | $162.76 | 2024 | Indigo System |
| Abbvie INC. | $162.36 | 2021-2024 | |
| Boston Scientific Corporation | $147.46 | 2019-2023 | Wavewriter Alpha Prime 16, Watchman Access System |
| Amgen INC. | $143.72 | 2019-2024 | Repatha, Otezla, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $135.02 | 2019-2022 | |
| Abbott Laboratories | $100.18 | 2021-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.10 | 2019-2024 | Jardiance |
| Lucid Diagnostics INC. | $80.41 | 2022-2023 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Oliva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.